High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.

ABSTRACT:

Introduction

This paper presents results from Cohort B (rearranged during transfection [RET], fusion-positive) of the Blood First Assay Screening Trial in patients with advanced non-small cell lung cancer (NSCLC) screened for genetic alterations using blood-based next-generation sequencing.

Material and methods

Adults with advanced RET fusion-positive NSCLC received alectinib 900 mg twice daily (BID) in Phase I. Enrolment closed prematurely with Phase II uninitiated.

Results

Among eight treated patients, confirmed best overall responses in evaluable patients were stable disease (4/5) and progressive disease (1/5). One dose-limiting toxicity (death, unknown cause) was considered by the investigator to be related to treatment and underlying disease. Seriou

SUBMITTER: Dziadziuszko R 

PROVIDER: S-EPMC10883190 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature